Reviva Pharmaceuticals I...
(RVPH)
undefined
undefined%
At close: undefined
2.69
2.48%
After-hours Dec 13, 2024, 07:59 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue,
expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | 724.74K | - | - |
| Gross Profit | - | - | - | -724.74K | - | - |
| Operating Income | -39,503.60B | -24.31M | -10.10M | -2.43M | -376.86K | -1.12M |
| Interest Income | - | 182.80K | - | 105.18K | 201.00 | - |
| Pretax Income | -39.24M | -24.32M | -8.52M | -3.78M | -846.03K | -1.68M |
| Net Income | -39,260.80B | -24.34M | -8.52M | -3.78M | -846.83K | -1.68M |
| Selling & General & Admin | 8,083.80B | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| Research & Development | 31,419.80B | 18.95M | 4.85M | 295.15K | 195.74K | 946.30K |
| Other Expenses | - | - | - | - | - | -0.00 |
| Operating Expenses | 39,503.60B | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Interest Expense | - | 182.80K | 2.41K | 1.45M | 469.37K | - |
| Selling & Marketing Expenses | - | - | - | - | - | - |
| Cost & Expenses | 39.50M | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Income Tax | -16.95B | 20.78K | 6.00K | 800.00 | 800.00 | 800.00 |
| Shares Outstanding (Basic) | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | - |
| Shares Outstanding (Diluted) | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | - |
| EPS (Basic) | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | - |
| EPS (Diluted) | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | - |
| EBITDA | -39,503.60B | -24.11M | -10.10M | -2.33M | -376.01K | -1.12M |
| Depreciation & Amortization | - | 194.71K | 236.56K | 105.77K | 846.00 | 1.02K |